Calcilytic NPSP795 Increases Plasma Calcium and PTH in an Autosomal Dominant Hypocalcemia Type 1 Mouse Model

Calcilytics are calcium‐sensing receptor (CaSR) antagonists that reduce the sensitivity of the CaSR to extracellular calcium. Calcilytics have the potential to treat autosomal dominant hypocalcemia type 1 (ADH1), which is caused by germline gain‐of‐function CaSR mutations and leads to symptomatic hy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JBMR Plus
Autors principals: Hannan, Fadil M, Gorvin, Caroline M, Babinsky, Valerie N, Olesen, Mie K, Stewart, Michelle, Wells, Sara, Cox, Roger D, Nemeth, Edward F, Thakker, Rajesh V
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574706/
https://ncbi.nlm.nih.gov/pubmed/33103030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbm4.10402
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars